title: Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis.
abstract: OBJECTIVE
  To compare the usability of a new certolizumab pegol (CZP) autoinjector with the adalimumab, etanercept, and golimumab devices in patients with rheumatoid arthritis.
  
  
  METHODS
  Two identical studies were performed in 2013 and 2016; patients performed a simulated self-injection with the CZP autoinjector and the most up-to-date device versions at the time in a randomized, consecutive sequence. The primary end point was the ranking of the four autoinjectors in order of preference. Device usability and intuitiveness were assessed across a range of secondary and exploratory end points.
  
  
  RESULTS
  The 2013 and 2016 study populations included 76 patients each; a significant majority (2013: 67%; 2016: 59%) ranked the CZP autoinjector as their most preferred device (p < 0.001). Most patients agreed that the CZP autoinjector was easier to use, start, and manipulate, and were more willing to use it than the comparator devices (p < 0.001 for all pairwise comparisons with CZP). Likert score differences also favored the CZP autoinjector regarding how easy it was to determine injection completion. The CZP autoinjector was associated with a low rate of use error.
  
  
  CONCLUSIONS
  In both studies, the CZP autoinjector was the preferred choice compared to the alternative devices and was associated with a high level of patient satisfaction.
authors: a UCB Celltech , Slough , UK.
authors: Barbara
authors: B
authors: Domańska
authors: b UCB Pharma , Raleigh , NC , USA.
authors: Brenda
authors: B
authors: VanLunen
authors: b UCB Pharma , Raleigh , NC , USA.
authors: Luke
authors: L
authors: Peterson
authors: c UCB Pharma , Brussels , Belgium.
authors: Irina
authors: I
authors: Mountian
authors: d Department of Rheumatology , University of Colorado School of Medicine , Denver , CO , USA.
authors: Michael
authors: M
authors: Schiff
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068582:Certolizumab Pegol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D000068582:Certolizumab Pegol
keywords: Autoinjector; certolizumab pegol; patient preference; rheumatoid arthritis; usability